Masimo is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors.

 
 
  • Oxygen Reserve Index (ORi™)
  • A noninvasive and continuous parameter that provides insight into a patient’s oxygen reserve
 
  • rainbow® Pulse CO-Oximetry
  • The Masimo rainbow SET™ platform has the unique ability to measure dyshemoglobins and total hemoglobin concentration.
 
 
  • CCHD Screening
  • Reliable, Accurate Screening for Critical Congenital Heart Disease (CCHD) with Masimo SET®

News & Media

 
  • August 13, 2018
  • Southampton, United Kingdom
  • Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers investigated whether home pulse oximetry monitoring might be a useful initial screening method of determining which children with down syndrome (DS) […]
  • Juli 27, 2018
  • Lebanon, New Hampshire
  • Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Dartmouth-Hitchcock Medical Center investigated the impact of an integrated clinical monitoring system, using various Masimo technologies and dev […]
  • Juli 16, 2018
  • IIzmit, Turkey
  • Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Kocaeli University in Turkey compared the performance of conventional fluid management (CFM) to goal-directed fluid management (GDFM) using Masim […]
  • März 2, 2018
  • Masimo Personal Health
  • MightySat is for people who want to improve their health, wellness, or fitness by providing key measurements that are more accurate & not available on other health and wellness devices. […]
  • Februar 23, 2018
  • Patient Safety Movement
  • The Patient Safety Movement Foundation believes reaching ZERO preventable deaths in hospitals by 2020 (0X2020™) is not only the right goal, but an attainable one with the […]
  • Mai 1, 2017
  • 2016 Masimo Annual Report
  • 2016 Masimo Annual Report - Through Movement. The first phase of our 10-year plan was to invest in R&D and key functional areas, allowing the company to gain a worldwide […]

Next Generation SedLine is not licensed for sale in Canada.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.